

Myocardial Infarction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/MA5510D85118EN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: MA5510D85118EN

Abstracts

The 7 major myocardial infarction markets reached a value of US\$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.94% during 2024-2034.

The myocardial infarction market has been comprehensively analyzed in IMARC's new report titled "Myocardial Infarction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myocardial infarction, also known as a heart attack, is a life-threatening condition that develops when blood flow to the heart muscle is blocked, leading to tissue damage. The most prominent symptom is severe and persistent chest pain or discomfort that may spread to the arms, neck, jaw, or back. This pain is often accompanied by shortness of breath, sweating, nausea, lightheadedness, and an overwhelming sense of anxiety. Some patients may also experience unusual fatigue, heart palpitations, a feeling of indigestion, etc. The diagnosis of myocardial infarction involves a combination of medical history evaluation, physical examination, and diagnostic tests. The healthcare provider will inquire about the patient's symptoms, risk factors, and medical history. During the physical exam, they may monitor heart and lung conditions, check blood pressure, and assess overall signs of distress. Various diagnostic procedures, such as an electrocardiogram (ECG), blood tests, imaging techniques like echocardiography or coronary angiography, etc., are also performed to confirm the diagnosis. These tests help to identify abnormal changes in the heart's electrical activity, detect the presence of certain enzymes released during a heart attack, and visualize the blood flow to the heart.

The increasing cases of coronary artery diseases in which plaque builds up on the inner walls of the arteries and reduces blood flow to the heart muscle are primarily driving the

myocardial infarction market. Furthermore, the rising prevalence of various associated risk factors, including high cholesterol levels, excessive alcohol consumption, smoking, lack of physical activity, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of beta-blockers, such as metoprolol, bisoprolol, carvedilol, etc., since they decrease the workload on the heart by slowing the heart rate and lowering blood pressure, thereby promoting healing and reducing the likelihood of future heart attacks, is also creating a positive outlook for the market. Moreover, the increasing utilization of radial access surgery on account of its several associated benefits, including a lower risk of access-site complications, better patient comfort, early mobilization, etc., is further augmenting the market growth. Apart from this, the escalating demand for drug-eluting stents, which have drastically reduced the incidence of restenosis and enhanced the effectiveness of stent placement, is expected to drive the myocardial infarction market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the myocardial infarction market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myocardial infarction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myocardial infarction market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the myocardial infarction market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the myocardial infarction market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current myocardial infarction marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the myocardial infarction market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the myocardial infarction market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the myocardial infarction market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of myocardial infarction across the seven major markets?

What is the number of prevalent cases (2018-2034) of myocardial infarction by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of myocardial infarction by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of myocardial infarction by type across the seven major markets?

How many patients are diagnosed (2018-2034) with myocardial infarction across the seven major markets?

What is the size of the myocardial infarction patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of myocardial infarction?

What will be the growth rate of patients across the seven major markets?

Myocardial Infarction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for myocardial infarction drugs across the

seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myocardial infarction market?

What are the key regulatory events related to the myocardial infarction market?

What is the structure of clinical trial landscape by status related to the myocardial infarction market?

What is the structure of clinical trial landscape by phase related to the myocardial infarction market?

What is the structure of clinical trial landscape by route of administration related to the myocardial infarction market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MYOCARDIAL INFARCTION - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 MYOCARDIAL INFARCTION - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 MYOCARDIAL INFARCTION - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Epidemiology by Type (2018-2034)
 - 7.2.6 Diagnosed Cases (2018-2034)
 - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Epidemiology by Type (2018-2034)
 - 7.3.6 Diagnosed Cases (2018-2034)
 - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Epidemiology by Type (2018-2034)
 - 7.4.6 Diagnosed Cases (2018-2034)
 - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Epidemiology by Type (2018-2034)
 - 7.5.6 Diagnosed Cases (2018-2034)
 - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Epidemiology by Type (2018-2034)
 - 7.6.6 Diagnosed Cases (2018-2034)

7.6.7 Patient Pool/Treated Cases (2018-2034)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (2018-2034)

7.7.4 Epidemiology by Gender (2018-2034)

7.7.5 Epidemiology by Type (2018-2034)

7.7.6 Diagnosed Cases (2018-2034)

7.7.7 Patient Pool/Treated Cases (2018-2034)

7.8 Epidemiology Scenario - Spain

7.8.1 Epidemiology Scenario (2018-2023)

7.8.2 Epidemiology Forecast (2024-2034)

7.8.3 Epidemiology by Age (2018-2034)

7.8.4 Epidemiology by Gender (2018-2034)

7.8.5 Epidemiology by Type (2018-2034)

7.8.6 Diagnosed Cases (2018-2034)

7.8.7 Patient Pool/Treated Cases (2018-2034)

7.9 Epidemiology Scenario - Japan

7.9.1 Epidemiology Scenario (2018-2023)

7.9.2 Epidemiology Forecast (2024-2034)

7.9.3 Epidemiology by Age (2018-2034)

7.9.4 Epidemiology by Gender (2018-2034)

7.9.5 Epidemiology by Type (2018-2034)

7.9.6 Diagnosed Cases (2018-2034)

7.9.7 Patient Pool/Treated Cases (2018-2034)

8 MYOCARDIAL INFARCTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment

8.2 Treatment Algorithm

9 MYOCARDIAL INFARCTION - UNMET NEEDS

10 MYOCARDIAL INFARCTION - KEY ENDPOINTS OF TREATMENT

11 MYOCARDIAL INFARCTION - MARKETING PRODUCTS

11.1 List of Myocardial Infarction Marketed Drugs Across the Top 7 Markets

- 11.1.1 Lovenox (Enoxaparin sodium) - Sanofi
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Retavase (Reteplase) - Chiesi USA, Inc
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Repatha (Evolocumab) - Amgen
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 TNKase (Tenecteplase) - Genentech
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Plavix (Clopidogrel) - Sanofi
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 MYOCARDIAL INFARCTION - PIPELINE DRUGS

- 12.1 List of Myocardial Infarction Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 GNR-060 - GENERIUM Pharmaceuticals
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 FDY-5301 - Faraday Pharmaceuticals
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 Dutoglipatin Tartrate - Recardio
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 Zalunfiban - Celecor Therapeutics
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. MYOCARDIAL INFARCTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. MYOCARDIAL INFARCTION – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 MYOCARDIAL INFARCTION - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Myocardial Infarction - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Myocardial Infarction - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Myocardial Infarction - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Myocardial Infarction - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Myocardial Infarction - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Myocardial Infarction - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Myocardial Infarction - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Myocardial Infarction - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Myocardial Infarction - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Myocardial Infarction - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Myocardial Infarction - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Myocardial Infarction - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

- 15.6.2 Myocardial Infarction - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Myocardial Infarction - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Myocardial Infarction - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Myocardial Infarction - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Myocardial Infarction - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Myocardial Infarction - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Myocardial Infarction - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Myocardial Infarction - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Myocardial Infarction - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Myocardial Infarction - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Myocardial Infarction - Access and Reimbursement Overview

16 MYOCARDIAL INFARCTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 MYOCARDIAL INFARCTION MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 MYOCARDIAL INFARCTION MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Myocardial Infarction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/MA5510D85118EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MA5510D85118EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

